In this third article in the series, we talk with Philip Seo, MD, MHS, about eosinophilic granulomatosis with polyangiitis (EGPA).

Michael Putman, MD |
In this third article in the series, we talk with Philip Seo, MD, MHS, about eosinophilic granulomatosis with polyangiitis (EGPA).
Michael Putman, MD |
Sharon Chung, MD, MAS, discusses specific recommendations for the treatment and management of ANCA-associated vasculitis from the latest ACR Guideline.
Michael Putman, MD |
Sharon A. Chung, MD, MAS, director of the vasculitis clinic at the University of California, San Francisco, served as the principal investigator of the overall vasculitis guideline effort and talks about the process here.
On May 6, the U.S. Food & Drug Administration’s (FDA’s) Arthritis Advisory Committee narrowly voted in support of avacopan, a C5a receptor inhibitor, for the treatment of adult patients with anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis. Although the panelists were excited about the possibility of a steroid-sparing therapy, some raised questions about whether results from…
ATLANTA—The American College of Rheumatology (ACR), in partnership with the Vasculitis Foundation (VF), released three new guidelines for the treatment and management of systemic vasculitis. Vasculitis is a group of about 20 rare diseases that have inflammation of blood vessels in common, which can restrict blood flow and damage vital organs. The three guidelines cover…
Tryphina Adel Mikhail & Mary Bratovich Toth, MD |
In September 2019, a previously healthy, 9-year-old white girl presented to the emergency department following two months of sinusitis and unexplained fever responsive to ibuprofen. She presented with anorexia; a 9Â lb. weight loss; intermittent, nonbilious, nonbloody emesis; and occasional epistaxis with digital manipulation of the nose. Six weeks prior to admission, she had presented to…
Over the past 18 months, the ACR’s Quality of Care (QOC) Committee has helped produce an impressive number of resources that will help rheumatologists deliver the best possible care. Working through specific projects supervised under its Criteria, Guideline, Guidance, and Quality Measure subcommittees, the QOC Committee has developed new sets of disease criteria, clinical guidelines,…
A phase 3 trial described in The New England Journal of Medicine (NEJM) highlights the potential of a C5a receptor inhibitor, avacopan, for anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis.1 Avacopan may potentially offer a steroid-sparing option for the treatment of this serious disease. Current Treatment of ANCA-Associated Vasculitis Morbidity and mortality from ANCA-associated vasculitis have…
The ACR, in concert with the Vasculitis Foundation, released three new vasculitis guidelines online first in July, with a fourth slated for publication by the end of the year. These are the first ever to be produced and endorsed by the ACR and the Vasculitis Foundation. Although most of the recommendations are conditional, due to…
The FDA has approved anakinra to treat a rare autoinflammatory disease, deficiency of interleukin 1 receptor antagonist. The administration also approved a new rituximab biosimilar, Riabni, for multiple indications.